AG Caldwell Files Fraud Suit Against Glaxosmithkline

AG Caldwell Files Fraud Suit Against Glaxosmithkline 

 Petition for Civil Penalties and Damages
BATON ROUGE--Attorney General Buddy Caldwell, on behalf of the State of Louisiana, filed a civil action suit in the 19th JDC against GLAXOSMITHKLINE, LLC, formerly SMITHKLINE BEECHAM CORPORATION d/b/a GLASOSMITHKLINE; GLAXOSMITHKLINE, PLC (GSK).

The suit claims that GSK wrongfully and illegally marketed, priced, sold and promoted the diabetes medication rosiglitazone maleate under the trade names Avandia®, Avandamet®, and Avandaryl®, violating Louisiana's Medical Assistance Programs Integrity Law (MAPIL), the Unfair Trade Practices and Consumer Protections Law and other state laws.

Attorney General Caldwell stated, "I am committed to pursuing those who prey on our citizens and our state Medicaid program. This type of exploitation jeopardizes our economy, our health and in some cases our lives. Our focus on these perpetrators sends a message of zero tolerance for such fraud and abuse."

The Attorney General's office works closely with the Department of Health and Hospitals on these cases.  DHH Secretary Bruce D. Greenstein said, "I welcome Attorney General Caldwell's tough stance in helping us protect precious Medicaid dollars. It is terribly disturbing that a company this size would take advantage of people by offering misleading information and take funds away from those who need it most. We are committed to rooting out abuse and misuse of Medicaid money wherever it occurs and to working with the Attorney General to ensure accountability for those who prey on the system."

The suit claims that Louisiana's Medicaid program paid GSK approximately $36,126,559.94 for fraudulently induced Avandia reimbursements. It is a civil action for civil fines, civil penalties, restitution and other monetary relief.

To view the entire petition, please see more resources.


Suggested Articles

An oncologist leader RBC Capital Markets interviewed expressed comfort that Trodelvy will succeed in earlier-line TNBC and in HR-positive disease.

Gilead Sciences is the latest drugmaker to settle Justice Department claims that its charity contributions were actually kickbacks.

J&J figures its partner Genmab owes a share of Darzalex Faspro royalties to Halozyme for its subcutaneous delivery tech. Genmab doesn't agree.